Analysis of Real-World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA.

WHY IT MATTERS

If you have a rare disease, this research shows the FDA is increasingly accepting real-world evidence from patient experiences and medical records to approve new treatments, which could mean faster access to medicines when traditional large-scale trials aren't feasible.

Researchers looked at how the FDA approves medicines for rare diseases from 2020 to 2024. They found that 129 rare disease drugs were approved during this time, and 25 of them (about 19%) used real-world data—information collected from patients outside of traditional clinical trials. Real-world data is becoming more important for rare diseases because it's often impossible to run large traditional studies when so few people have a disease.

Analysis of Real-World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA. Abstract: In the field of rare diseases-where traditional clinical trials are often impractical-real-world data (RWD) have emerged as a scientifically valid alternative to support regulatory decision making. This study systematically evaluates the utilization of RWD in orphan drug approvals by the FDA Center for Drug Evaluation and Research (CDER) over the past 5 years (2020-2024). We reviewed marketing applications for orphan drugs approved during this period, identifying those that included RWD. Each case was categorized based on the type and purpose of RWD use, sample size, FDA's evaluation, and label inclusion. A total of 129 orphan drugs were approved during this 5-year period, representing approximately 53% of all new drug approvals. Among these, 25 applications (19%) incorporated RWD, Authors: Kim et al. Journal: Clinical pharmacology and therapeutics MeSH: United States, Drug Approval, United States Food and Drug Administration, Orphan Drug Production, Humans, Rare Diseases, Marketing